scholarly journals Travel Characteristics and Yellow Fever Vaccine Usage Among US Global TravEpiNet Travelers Visiting Countries with Risk of Yellow Fever Virus Transmission, 2009–2011

2013 ◽  
Vol 88 (5) ◽  
pp. 954-961 ◽  
Author(s):  
Emily S. Jentes ◽  
Pauline Han ◽  
Mark D. Gershman ◽  
Sowmya R. Rao ◽  
Regina C. LaRocque ◽  
...  
Viruses ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1475
Author(s):  
Moussa Moïse Diagne ◽  
Marie Henriette Dior Ndione ◽  
Alioune Gaye ◽  
Mamadou Aliou Barry ◽  
Diawo Diallo ◽  
...  

Yellow fever virus remains a major threat in low resource countries in South America and Africa despite the existence of an effective vaccine. In Senegal and particularly in the eastern part of the country, periodic sylvatic circulation has been demonstrated with varying degrees of impact on populations in perpetual renewal. We report an outbreak that occurred from October 2020 to February 2021 in eastern Senegal, notified and managed through the synergistic effort yellow fever national surveillance implemented by the Senegalese Ministry of Health in collaboration with the World Health Organization, the countrywide 4S network set up by the Ministry of Health, the Institut Pasteur de Dakar, and the surveillance of arboviruses and hemorrhagic fever viruses in human and vector populations implemented since mid 2020 in eastern Senegal. Virological analyses highlighted the implication of sylvatic mosquito species in virus transmission. Genomic analysis showed a close relationship between the circulating strain in eastern Senegal, 2020, and another one from the West African lineage previously detected and sequenced two years ago from an unvaccinated Dutch traveler who visited the Gambia and Senegal before developing signs after returning to Europe. Moreover, genome analysis identified a 6-nucleotide deletion in the variable domain of the 3′UTR with potential impact on the biology of the viral strain that merits further investigations. Integrated surveillance of yellow fever virus but also of other arboviruses of public health interest is crucial in an ecosystem such as eastern Senegal.


2018 ◽  
Vol 64 (6) ◽  
pp. 498-500 ◽  
Author(s):  
Michelle Larissa Zini Lise ◽  
Michael Laurence Zini Lise

SUMMARY The Yellow Fever virus was isolated in 1927 and the disease is considered endemic and epidemic in tropical regions of South America and Africa, with thousands of new cases reported annually. Several side effects of the vaccine have already been reported. Although reports of skin rash secondary to the vaccine range from 0 to 15%, no image or detailed description of the lesions were found in the literature. Here we describe a rash on a toddler vaccinated to travel.


2018 ◽  
Author(s):  
Faria N. R. ◽  
Kraemer M. U. G. ◽  
Hill S. C. ◽  
Goes de Jesus J. ◽  
de Aguiar R. S. ◽  
...  

AbstractThe yellow fever virus (YFV) epidemic that began in Dec 2016 in Brazil is the largest in decades. The recent discovery of YFV in BrazilianAedes sp.vectors highlights the urgent need to monitor the risk of re-establishment of domestic YFV transmission in the Americas. We use a suite of epidemiological, spatial and genomic approaches to characterize YFV transmission. We show that the age- and sex-distribution of human cases in Brazil is characteristic of sylvatic transmission. Analysis of YFV cases combined with genomes generated locally using a new protocol reveals an early phase of sylvatic YFV transmission restricted to Minas Gerais, followed in late 2016 by a rise in viral spillover to humans, and the southwards spatial expansion of the epidemic towards previously YFV-free areas. Our results establish a framework for monitoring YFV transmission in real-time, contributing to the global strategy of eliminating future yellow fever epidemics.


2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Natalia Ingrid Oliveira Silva ◽  
Lívia Sacchetto ◽  
Izabela Maurício de Rezende ◽  
Giliane de Souza Trindade ◽  
Angelle Desiree LaBeaud ◽  
...  

1977 ◽  
Vol 26 (5) ◽  
pp. 985-989 ◽  
Author(s):  
Thomas H. G. Aitken ◽  
Robert E. Shope ◽  
Wilbur G. Downs

2017 ◽  
Vol 11 (8) ◽  
pp. e0005858 ◽  
Author(s):  
Sheila B. Agha ◽  
David P. Tchouassi ◽  
Armanda D. S. Bastos ◽  
Rosemary Sang

1967 ◽  
Vol 65 (4) ◽  
pp. 505-513 ◽  
Author(s):  
C. C. Draper

1. The methods used for clearing a vaccine substrain of 17 D yellow fever virus of contaminant avian leucosis viruses are described.2. Tests in animals and human subjects showed that the characteristics of the virus remained unchanged.


Author(s):  
Raphaëlle Klitting ◽  
Carlo Fischer ◽  
Jan F. Drexler ◽  
Ernest A. Gould ◽  
David Roiz ◽  
...  

As revealed by the recent resurgence of yellow fever virus (YFV) activity in the tropical regions of Africa and South America, YFV control measures need urgent rethinking. Over the last decade, most reported outbreaks occurred in, or eventually reached, areas of low vaccination coverage but suitable for virus transmission, with an unprecedented risk of expansion to densely populated territories in Africa, South America and Asia. As reflected in the World Health Organization’s initiative launched in 2017, it is high time to strengthen epidemiological surveillance to monitor accurately, viral dissemination and redefine vaccination recommendation areas. Vector-control and immunisation measures need to be adapted and vaccine manufacturing must be reconciled with an increasing demand. We will have to face more YF cases in the upcoming years hence, improving disease management through the development of efficient treatments will prove most beneficial. Undoubtedly, these developments will require in-depth descriptions of YFV biology at molecular, physiological and ecological levels. This second section of the two-part review describes the current state of knowledge and gaps regarding the molecular biology of YFV, along with an overview of the tools that can be used to manage the disease at the individual, local and global levels.


Sign in / Sign up

Export Citation Format

Share Document